GLP-1R Antibody - BSA Free

Immunohistochemistry: GLP-1R Antibody - BSA Free [NLS1205]

Immunohistochemistry: GLP-1R Antibody [NLS1205] - Analysis of GLP-1R in mouse pancreas.

Immunohistochemistry: GLP-1R Antibody - BSA Free [NLS1205]

Immunohistochemistry: GLP-1R Antibody [NLS1205] - Human pancreas (Islets of Langerhans).

Simple Western: GLP-1R AntibodyBSA Free [NLS1205]

Simple Western: GLP-1R Antibody [NLS1205] - Image shows a specific band for GLP-1R in 0.5 mg/mL of HEK293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Microarray: GLP-1R Antibody - BSA Free [NLS1205]

Microarray: GLP-1R Antibody [NLS1205] - Antibody was printed on custom arrays and incubated with fluorescently labeled human EDTA plasma. Microarray image submitted by a verified customer review.

Simple Western: GLP-1R Antibody - BSA Free [NLS1205] -

Simple Western: GLP-1R Antibody - BSA Free [NLS1205] - Effect of the administration of exendin‐4 on eNOS expression. (a) Capillary western blot of total eNOS & phosphorylated eNOS expression in the rat retina. The red box indicates the target protein. (b & c) Fold change in the expression of total eNOS (b) & phosphorylated eNOS (c) in the rat retina (n = 7 in control group; n = 6 in Hp + PBS group; n = 9 in other groups). (d & e) Capillary western blot & fold change in the expression of GLP‐1 receptors (GLP‐1R) (d), PI3K, & Akt (e) in the rat retina. *P < .05, significantly different from CSF group; #P < .05significantly different from noradrenaline without exendin‐4 group. (f) NO content in human retinal microvascular endothelial cells (n = 6, 5, 5, 6, 7, 5, & 6 for group of control, OGD, OGD + Ex‐4, OGD + Ex‐4 + Ex‐9–39‐L, OGD + Ex‐4 + Ex‐9–39‐H, OGD + Ex‐4 + l‐NAME‐L, & OGD + Ex‐4 + l‐NAME‐H, respectively). One‐way ANOVA with LSD or Dunnett's T3 test were performed. C, control group; HP, high pressure injury group; EX‐4, exendin‐4; s.c., subcutaneous injection of exendin‐4; i.v., intravitreal injection of exendin‐4; od, eye drops of exendin‐4; OGD, oxygen glucose deprivation model; EX‐9–39‐L, low concentration of exendin‐9‐39 (10 nM); EX‐9–39‐H, high concentration of exendin‐9‐39 (20 nM); l‐NAME‐l, low concentration of l‐NAME (50 μM); l‐NAME‐H, high concentration of l‐NAME (100 μM) Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/32232832), licensed under a CC-BY license. Not internally tested by Novus Biologicals.